These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 25526841)

  • 1. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.
    Sawyer LM; Wonderling D; Jackson K; Murphy R; Samarasekera EJ; Smith CH
    Pharmacoeconomics; 2015 Feb; 33(2):163-77. PubMed ID: 25526841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy.
    Spandonaro F; Ayala F; Berardesca E; Chimenti S; Girolomoni G; Martini P; Peserico A; Polistena B; Puglisi Guerra A; Vena GA; Altomare G; Calzavara Pinton P
    BioDrugs; 2014 Jun; 28(3):285-95. PubMed ID: 24567261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
    Villacorta R; Hay JW; Messali A
    Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for the treatment of adults with psoriasis.
    Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis.
    Sawyer L; Samarasekera EJ; Wonderling D; Smith CH
    Br J Dermatol; 2013 May; 168(5):1095-105. PubMed ID: 23374249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.
    Emery P; Van Keep M; Beard S; Graham C; Miles L; Jugl SM; Gunda P; Halliday A; Marzo-Ortega H
    Pharmacoeconomics; 2018 Aug; 36(8):1015-1027. PubMed ID: 29797186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis.
    Udkoff J; Eichenfield LF
    J Drugs Dermatol; 2017 Oct; 16(10):964-970. PubMed ID: 29036249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.
    Hamid R; Loveman C; Millen J; Globe D; Corbell C; Colayco D; Stanisic S; Gultyaev D
    Pharmacoeconomics; 2015 Apr; 33(4):381-93. PubMed ID: 25526842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
    Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
    Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
    Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
    J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
    Choy E; Richards S; Bowrin K; Watson P; Lloyd A; Sadosky A; Zlateva G
    Curr Med Res Opin; 2010 Apr; 26(4):965-75. PubMed ID: 20178405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
    Botteman MF; Hay JW; Luo MP; Curry AS; Wong RL; van Hout BA
    Rheumatology (Oxford); 2007 Aug; 46(8):1320-8. PubMed ID: 17545684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines.
    Mauskopf J; Samuel M; McBride D; Mallya UG; Feldman SR
    Pharmacoeconomics; 2014 Apr; 32(4):395-409. PubMed ID: 24469676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.
    Wang SH; Chi CC; Hu S
    Int J Dermatol; 2014 Sep; 53(9):1151-6. PubMed ID: 24738910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.